The experiences of patients with pulmonary. arterial hypertension receiving continuous intravenous infusion of epoprostenol (Flolan) and their support persons

被引:11
作者
Hall, Heather [1 ]
Cote, Joanne [2 ]
McBean, Althea [2 ]
Purden, Margaret [1 ]
机构
[1] McGill Univ, Jewish Gen Hosp, Sch Nursing, Ctr Nursing Res, Montreal, PQ H3T 1E2, Canada
[2] McGill Univ, Jewish Gen Hosp, Div Cardiol, Montreal, PQ H3T 1E2, Canada
来源
HEART & LUNG | 2012年 / 41卷 / 01期
关键词
Epoprostenol; Pulmonary arterial hypertension; Qualitative; Resilience; Support persons; Technology; QUALITY-OF-LIFE; RESILIENCE; THERAPY; HOME; PROSTACYCLIN;
D O I
10.1016/j.hrtlng.2011.05.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE: Little is known about the day-to-day experiences of patients and their support persons during the course of epoprostenol treatment for pulmonary arterial hypertension (PAH). The study objective was to describe the experiences of patients and their support persons adjusting to PAH and continuous intravenous epoprostenol. METHODS: A qualitative descriptive design with semistructured interviews was conducted jointly with the patient and his/her support person. Seven patients and their support persons (spouse, child, friend) were included. RESULTS: Patients demonstrated personal growth and resilience as they adapted to PAH. Four patient themes emerged: initial shock, figuring it out, giving life, and ongoing struggles. Themes specific to the support person included "their life is in my hands," pressure to perform, and continuation of my role. CONCLUSION: Nurses may assist these patients and support persons by teaching technical skills, problem-solving and troubleshooting strategies, mobilizing social support, and providing opportunities to reflect on lifestyle changes and long-term adjustment to PAH. Cite this article: Hall, H., Cote, J., McBean, A., & Purden, M. (2012, JANUARY/FEBRUARY). The experiences of patients with pulmonary arterial hypertension receiving continuous intravenous infusion of epoprostenol (Flolan) and their support persons. Heart & Lung, 41(1), 35-43. doi:10.1016/j.hrtlng.2011.05.007.
引用
收藏
页码:35 / 43
页数:9
相关论文
共 50 条
[41]   Marked Hemodynamic Improvements by High-Dose Epoprostenol Therapy in Patients With Idiopathic Pulmonary Arterial Hypertension [J].
Akagi, Satoshi ;
Nakamura, Kazufumi ;
Miyaji, Katsumasa ;
Ogawa, Aiko ;
Kusano, Kengo Fukushima ;
Ito, Hiroshi ;
Matsubara, Hiromi .
CIRCULATION JOURNAL, 2010, 74 (10) :2200-2205
[42]   Intravenous treprostinil infusion via a fully implantable pump for pulmonary arterial hypertension [J].
Ralf Ewert ;
Manuel J. Richter ;
Regina Steringer-Mascherbauer ;
Ekkehard Grünig ;
Tobias J. Lange ;
Christian F. Opitz ;
Christian Warnke ;
Hossein-Ardeschir Ghofrani .
Clinical Research in Cardiology, 2017, 106 :776-783
[43]   Transition from intravenous epoprostenol to oral or subcutaneous therapy in pulmonary arterial hypertension: A retrospective case series and systematic literature review [J].
Park, Kirily ;
Ostrow, David ;
Levy, Robert D. ;
Swiston, John .
CANADIAN RESPIRATORY JOURNAL, 2011, 18 (03) :157-162
[44]   EPITOME-4, a phase 3b study evaluating a new formulation of epoprostenol sodium in pulmonary arterial hypertension following switch from Flolan® [J].
Tamura, Yuichi ;
Ono, Tomohiko ;
Fukuda, Keiichi ;
Satoh, Toru ;
Sasayama, Shigetake .
EUROPEAN RESPIRATORY JOURNAL, 2013, 42
[45]   Subcutaneous implantation of a new intravenous pump system for prostacyclin treatment in patients with pulmonary arterial hypertension [J].
Desole, Susanna ;
Velik-Salchner, Corinna ;
Fraedrich, Gustav ;
Ewert, Ralf ;
Kaehler, Christian M. .
HEART & LUNG, 2012, 41 (06) :599-605
[46]   Plasma brain natriuretic peptide as a parameter to assess efficacy of continuous intravenous infusion of prostacyclin (epoprostenol) to treat severe primary pulmonary hypertension: a case report [J].
Wakaumi, M ;
Shiga, T ;
Nozaki, K ;
Fujiu, K ;
Shimaya, K ;
Ishizuka, N ;
Matsuda, N ;
Kasanuki, H .
HEART AND VESSELS, 2000, 15 (03) :144-146
[47]   Incidence of Bloodstream Infection in Patients with Pulmonary Hypertension under Intravenous Epoprostenol or Iloprost-A Multicentre, Retrospective Study [J].
Camara, Raquel Paulinetti ;
Coelho, Francisco das Neves ;
Cruz-Martins, Natalia ;
Marques-Alves, Patricia ;
Castro, Graca ;
Baptista, Rui ;
Ferreira, Filipa .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (07)
[48]   Plasma brain natriuretic peptide as a parameter to assess efficacy of continuous intravenous infusion of prostacyclin (epoprostenol) to treat severe primary pulmonary hypertension: a case report [J].
Michi Wakaumi ;
T. Shiga ;
Katsuhiro Nozaki ;
Katsuhito Fujiu ;
Kazuhiro Shimaya ;
Naoko Ishizuka ;
Naoki Matsuda ;
Hiroshi Kasanuki .
Heart and Vessels, 2000, 15 :144-146
[49]   EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension [J].
Sitbon, Olivier ;
Delcroix, Marion ;
Bergot, Emmanuel ;
Boonstra, Anco B. ;
Granton, John ;
Langleben, David ;
Escribano Subias, Pilar ;
Galie, Nazzareno ;
Pfister, Thomas ;
Lemarie, Jean-Christophe ;
Simonneau, Gerald .
AMERICAN HEART JOURNAL, 2014, 167 (02) :210-217
[50]   Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: Data from the French pulmonary hypertension registry [J].
Bergot, Emmanuel ;
Sitbon, Olivier ;
Cottin, Vincent ;
Prevot, Gregoire ;
Canuet, Matthieu ;
Bourdin, Arnaud ;
de Groote, Pascal ;
Rottat, Laurence ;
Gressin, Virginie ;
Jais, Xavier ;
Humbert, Marc ;
Simonneau, Gerald .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 172 (03) :561-567